Future COVID vaccines must be better; Science rushes to answer

SOURCES

David L. Hoey, President and CEO of Vaxxas, Cambridge, MA, and Brisbane, Australia.

Pablo Penaloza-MacMaster, PhD, Assistant Professor of Microbiology and Immunology, Feinberg School of Medicine, Northwestern University, Chicago.

Jasdave Chahal, PhD, Co-Founder and Chief Scientist, Tiba Biotech, Cambridge, MA, and Brisbane, Australia.

Vaxart press release: “Vaxart has announced positive first-line Phase II clinical study data demonstrating the safety and immunogenicity of its COVID-19 pill vaccine candidate only in Wuhan.”

Mark Herr, Spokesperson, Vaxart Inc.

The Commonwealth Fund: “Two years of US vaccines against COVID-19 have prevented millions of hospitalizations and deaths.”

The Lancet infectious diseases: “Global impact of the first year of vaccination against COVID-19: a mathematical modeling study.”

CDC: COVID Data Tracker, “Needle Fears and Phobias—Find Ways to Manage.”

US Specialty Formulations Press Release: “Research Demonstrates Benefits of Oral COVID-19 Vaccine.”

CanSino Biologics Inc. Statement: “Inside Information”.

Coalition for Epidemic Preparedness Innovations: Statement by e-mail; Press releases: “Future-proof race for coronavirus vaccines;.” “Coming in from the cold: Needle-free patch technology for mRNA vaccines aims to end the need for frozen storage and improve access.”

Executive Office of the President: “Statement of Administrative Policy”.

Science: “RBD mosaic nanoparticles protect against challenge by various sarbecoviruses in animal models.”

Caltech press release: “Nanoparticle vaccine protects against a spectrum of variants and viruses associated with the origin of COVID-19.”

US Government Accountability Office. “Operation Warp Speed.”

Bharat Biotech International Limited press release: “Bharat biotech launches iNCOVACC: the world’s first intranasal COVID vaccine for primary series and heterologous booster.”

The Lancet preprints: “Immunogenicity and Safety of BBV154 (iNCOVACC®), an Intranasal SARS-CoV-2 Vaccine, Compared to Intramuscular Covaxin® in Healthy Adults: A Randomized, Open-Label, Phase 3 Clinical Trial.”

Cell: “Paediatric intranasal pediatric parainfluenza virus-vectored SARS-CoV-2 vaccine is protective in monkeys.”

National Institute of Allergy and Infectious Diseases Press Release: “NIAID Issues New Awards to Support Pancoronavirus Vaccine Development.”

CEPI Press Release: “CEPI and DIOSynVax Partner to Develop Broadly Protective Vaccine Against Betacoronavirus.”

CDC: “Understanding how COVID-19 vaccines work”.

Natural immunology: “The T cell immune response against SARS-CoV-2.”

National Institutes of Health: “T cells protect against COVID-19 in the absence of an antibody response.”

PNAS: “Vaccine-induced systemic and mucosal T-cell immunity against SARS-CoV-2 viral variants.”

Cell reports: “Pre-existing immunity modulates responses to mRNA boosters.”

University of Minnesota Center for Infectious Disease Research and Policy: “Coronavirus Vaccine R&D Roadmap”.

NIH Press Release: “2NIAID Studies Highlight Potential of Natal COVID-10 Vaccine.”

US Specialty Formulations Press Release: “Research Demonstrates Benefits of Oral COVID-19 Vaccine. »